Peptide RX

back to claim graph

proof receipt / fold

FOXO3 WT

Structure prediction with public confidence context.

grade B status complete receipt d9c17ec8d706 proof 67%

what this node claims

FOXO3 WT

Structure prediction with public confidence context.

Open source surface

vertical proof spine

  1. 01 FOXO3 WT fold / grade B / 54% 3 debt
  2. 02 AlphaFold metrics / FOXO3 alphafold metric / grade B / 70% 1 debt
  3. 03 Initial digest — FOXO3 finding / grade C / 47% 1 debt
  4. 04 fold.complete timeline event / grade C / 55%
  5. 05 FOXO3 target / grade B / 70% 1 debt

evidence / risk instrument

45%
thin proof
structure evidence gates risk export lineage 45
visible debt pressure 50%
51%structurethin
pLDDT 50.66
55%evidencethin
grade C
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
67%lineageusable
incomplete spine

proof completeness

67% missing candidate, export
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

confidence band
low
confidence pct
50.66
coverage available
false
gene
FOXO3
has structure
true
pae available
false
plddt avg
50.66
sequence length
0
variant
WT

AlphaFold metrics visual

Low-confidence regions present

50.7

673 residues / min 30.38 / max 97.69 / source alphafold db

PAE matrix for linked target
Very high 9.2% 62 residues / >=90
Confident 4.2% 28 residues / 70-89
Low 17.5% 118 residues / 50-69
Very low 69.1% 465 residues / <50

weak structural context; downstream claims should be conservative

Near-complete coverage / observed 673 of 673 residues.

  • residues 240-622 / mean 43.05
  • residues 1-153 / mean 47.37
  • residues 630-673 / mean 45.99
  • residues 201-202 / mean 64.41
proof debt register

Visible limits, not hidden cleanup.

50%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

low computational-only status add independent evidence, challenge result, or witness review before strengthening
low low-confidence AlphaFold regions likely attach pLDDT series, PAE matrix, or coverage evidence
medium no candidate yet leave visible until a stronger public receipt resolves it
medium missing PAE/context where AlphaFold DB is not linked attach pLDDT series, PAE matrix, or coverage evidence
high low evidence grade attach graded finding with source-linked evidence
medium missing functional-site annotations link target annotation, GO term, or binding-site context

weakness and challenge edges

What would stop this from becoming stronger.

debt severity export claim strength next proof needed
computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
low-confidence AlphaFold regions likely low visible watch attach pLDDT series, PAE matrix, or coverage evidence
no candidate yet medium visible weakens leave visible until a stronger public receipt resolves it
missing PAE/context where AlphaFold DB is not linked medium visible weakens attach pLDDT series, PAE matrix, or coverage evidence
low evidence grade high blocks weakens attach graded finding with source-linked evidence
missing functional-site annotations medium visible weakens link target annotation, GO term, or binding-site context

what supports it

target has structure prediction target:6e5eea04-c402-46b9-a193-9d22f96a11fb -> fold:c47c84a6-42be-4197-83f9-3b12f34f733c folds_to / B / 0.507

what it supports

measured by AlphaFold confidence context fold:c47c84a6-42be-4197-83f9-3b12f34f733c -> alphafold_metric:c47c84a6-42be-4197-83f9-3b12f34f733c measured_by / B / 0.507
evidence finding attached fold:c47c84a6-42be-4197-83f9-3b12f34f733c -> finding:b56e2f50-20ac-41f9-a8c5-bdb5540db468 supports / C / 0.6
timeline records state change fold:c47c84a6-42be-4197-83f9-3b12f34f733c -> timeline_event:30 records / C / 0.5

Research-use boundary

This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.